6424-87-9

Usage

Uses

Used in Dye Industry:
1-Amino-4-[(3-cyanophenyl)amino]-9,10-dihydro-9,10-dioxoanthracene-2-sulfonic acid sodium salt is used as a dye for various applications due to its blue color and solubility in alcohol. Its light fastness, soaping, perspiration fastness, and other properties make it suitable for use in textiles, paints, and other industries where colorfastness is important.
Used in Chemical Industry:
1-Amino-4-[(3-cyanophenyl)amino]-9,10-dihydro-9,10-dioxoanthracene-2-sulfonic acid sodium salt can be used as an intermediate in the synthesis of other organic compounds, such as pharmaceuticals, agrochemicals, and dyes. Its unique chemical structure and properties make it a valuable building block for the development of new compounds with specific functions and applications.
Used in Research and Development:
1-Amino-4-[(3-cyanophenyl)amino]-9,10-dihydro-9,10-dioxoanthracene-2-sulfonic acid sodium salt can be used as a research compound to study its chemical properties, reactivity, and potential applications in various fields. Its unique structure and properties can provide insights into the development of new materials, catalysts, and other chemical processes.

Preparation

1-Amino-4-bromo-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid?and?3-Aminobenzonitrile?with copper and sodium carbonate in the presence of reaction.

Standard

Light Fastness

Fading

Stain

ISO

5-6

InChI:InChI=1/C21H13N3O5S.Na/c22-10-11-4-3-5-12(8-11)24-15-9-16(30(27,28)29)19(23)18-17(15)20(25)13-6-1-2-7-14(13)21(18)26;/h1-9,24H,23H2,(H,27,28,29);/q;+1/p-1

Upstream product

• 6258-06-6 sodium 1-amino-4-bromoanthraquinone-2-sulfonate 
• 2237-30-1 m-cyanoaniline 

Relevant academic research and scientific papers

Development of 1-Amino-4-(phenylamino)anthraquinone-2-sulfonate Sodium Derivatives as a New Class of Inhibitors of RANKL-Induced Osteoclastogenesis

A series of 1-amino-4-(phenylamino)anthraquinone-2-sulfonate sodium derivatives was synthesized and evaluated for osteoclast inhibition using a TRAP-staining assay. Among them, two compounds, LCCY-13 and LCCY-15, dose-dependently suppressed receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation. Moreover, the cytotoxicity assay on RAW264.7 cells suggested that the inhibition of osteoclastic bone resorption by these compounds was not a result of their cytotoxicity. Further, the inhibitory activities of compounds LCCY-13 and LCCY-15 were further confirmed by including specific inhibition of NFATc1 expression levels in nuclei using an immunofluorescent analysis. In addition, LCCY-13 and LCCY-15 also significantly attenuated the bone resorption activity of osteoclasts according to a pit formation assay. Thus, a new class of 1-amino-4-(phenylamino)anthraquinone-2-sulfonate sodium compounds might be considered as an essential lead structure for the further development of anti-resorptive agents.

ANTHRAQUINONE COMPOUNDS AND THEIR USES

The present invention relates to a compound comprising a substituted or unsubstituted anthraquinone, or a salt or isomer thereof, for use in treating a disorder caused by or associated with dysfunctional ion channel activity. The invention finds utility in the treatment of disorders associated with smooth muscle tone and contraction, such as arterial hypertension; myocardial infarction; faecal incontinence; constipation; gastro oesophageal reflux; impaired gastrointestinal passage; urinary incontinence; erectile dysfunction; and asthma.

Anthraquinone compounds and their uses

This invention relates to compounds comprising a substituted or unsubstituted anthraquinone, or a salt or isomer thereof, for use in treating a disorder caused by or associated with dysfunctional ion channel activity; for example, BK Channel activity. The compounds of the present invention find utility in the treatment such as urinary incontinence, irritable bowel syndrome, diabetes and arterial hypertension, cardiovascular diseases including myocardial infarction, erectile dysfunction and airway constriction.